RxDoctor Payments Data

Austin Schlie, DO

Family Medicine · Leo, INNPI 1871721332

Payments from drug & device makers

$10,796in general payments, 2019–2025

Across 695 payments — averaging $15.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$963
  • Corium, LLC$857
  • Pfizer$730
  • Amgen$594
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$10,64899%
  • Education$1481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,796 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$119,888
Medicare patients
269
Services billed
2,229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban285$162,796
MounjaroTirzepatide79$86,230
FarxigaDapagliflozin Propanediol62$84,307
OzempicSemaglutide50$78,915
Soliqua 100-33Insulin Glargine/Lixisenatide68$76,367
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$74,108
JardianceEmpagliflozin59$63,847
TrulicityDulaglutide38$44,143
ProliaDenosumab13$23,157
XareltoRivaroxaban13$21,713
LinzessLinaclotide28$21,089
MyrbetriqMirabegron35$19,257
GlyxambiEmpagliflozin/Linagliptin12$19,228
EntrestoSacubitril/Valsartan27$15,552
Repatha SureclickEvolocumab19$15,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$730$162,796285 claims
Lilly USA, LLCMounjaro, Trulicity$963$130,373117 claims
Boehringer IngelheimJardiance, Glyxambi, Tradjenta$300$92,91388 claims
AstraZenecaFarxiga$1,478$84,30762 claims
Novo NordiskOzempic$510$78,91550 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$228$76,36768 claims
GSKTrelegy Ellipta$544$74,10873 claims
AbbVieLinzess, Synthroid$1,898$23,79059 claims
AmgenProlia$594$23,15713 claims
Johnson & JohnsonXarelto$56$21,71313 claims
Astellas Pharma US IncMyrbetriq$66$19,25735 claims
MerckJanuvia, Dulera$129$19,11142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Leo

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →